Skip to content
Blimdata

For AI & pharma teams

Diverse imaging data.Regulator-ready.

Acquire radiologist-annotated studies from the populations your training set does not represent — delivered as structured datasets with the provenance and de-identification record your regulatory and legal teams will ask for.

Request dataset accessReview our security model

  • Format

    DICOM with structured annotation and clinical metadata.

  • Annotation

    Licensed radiologists, AI-assisted, adjudicated review.

  • Compliance

    HIPAA Safe Harbor de-identification, NDPA aligned.

  • Commercial

    Subscription, batch acquisition or commissioned collection.

The problem you have

Your model works.You just cannot prove where.

Diagnostic performance does not transfer cleanly across populations, and regulators have stopped treating that as an academic concern. If your training and validation data does not include the patients your product will be used on, the gap shows up at exactly the wrong moment — in a submission, in a post-market review, or in the field.

  • Model performance degrades on populations absent from training data.
  • Demographic coverage has moved from a research nicety to a submission question.
  • Retrofitting diversity into a validated model is far more expensive than sourcing it up front.
  • The data exists — it has simply never been packaged in a form you can buy.
What you receive
De-identified DICOM Pixel data intact, headers cleaned
Structured annotation JSON · masks · bounding boxes
Clinical metadata Modality, region, acquisition
Provenance record Source site class, date range
De-identification attestation Method and validation result

Every release is versioned. Datasets grow; prior versions stay reproducible.

Why the annotation holds up

Labels are the product. We treat them that way.

Raw pixels are cheap. What makes a dataset worth licensing is whether a clinician would stand behind every label in it.

Who labels

Licensed radiologists

Annotation is performed by credentialed local radiologists working in a secure browser workspace, not by general-purpose crowd labour.

How it scales

AI-assisted, human-decided

Server-side models pre-segment structures and propose bounding boxes. The clinician confirms, corrects or rejects each proposal — which is what makes review fast without making it automatic.

How it is checked

Adjudicated quality control

A defined proportion of studies is double-read, with disagreements adjudicated by a senior reader. Inter-reader agreement is measured, not assumed.

What you can verify

Annotation provenance

Each label carries the annotation protocol version and the review path it went through, so you can defend the dataset rather than just describe it.

Dataset coverage

Modalities in the pipeline.

Coverage grows with every partner hospital we onboard. Current and committed volumes are shared under NDA rather than published.

CR / DX Under NDA

X-ray

Chest, musculoskeletal and abdominal plain film — the highest-volume archive in most partner sites.

CT Under NDA

Computed tomography

Head, chest and abdominal series, including multi-phase contrast studies.

MR Under NDA

Magnetic resonance

Neuro and musculoskeletal sequences, T1 / T2 / FLAIR and diffusion.

US Under NDA

Ultrasound

Obstetric, abdominal and cardiac studies, including cine loops.

MG Onboarding

Mammography

Screening and diagnostic views, with priors where available.

— On request

Commissioned collection

Where an archive does not yet hold what you need, we can scope prospective collection with partner sites.

Volumes and pathology breakdowns are shared under NDA.

Commercial models

Three ways to buy.

Which one fits depends on whether you are exploring, training, or preparing a submission.

Model 01

Subscription

Recurring access to a versioned dataset that grows as partner sites onboard. Suits ongoing training and continuous evaluation programmes.

Model 02

Batch acquisition

A one-off, fixed-scope acquisition of a defined cohort. Suits a specific submission, benchmark or validation study with a known endpoint.

Model 03

Commissioned collection

Where the pathology or protocol you need is not already in an archive, we scope prospective collection with partner sites. Longest lead time, highest specificity.

Diligence

Built to survive your legal review.

De-identification follows the HIPAA Safe Harbor method — all 18 identifiers removed from DICOM metadata, with separate detection and redaction of burned-in text in pixel data. The pipeline is aligned to the Nigeria Data Protection Act, and source institutions remain the data controller for their own archives.

Every licensed release carries a provenance record and a de-identification attestation describing the method applied and the validation result. Access to the data room is role-based and least-privilege, and every read, export and permission change is written to an immutable audit log.

We will not pretend this removes your obligations. It gives your counsel a documented chain to review rather than a vendor assurance to accept.

A dataset you cannot defend in a submission is not an asset. It is a liability with a licence fee.

Licensee questions

Before you ask.

Can we evaluate a sample before committing?

Yes. We release an evaluation sample under NDA so your team can inspect real studies, real annotations and the metadata schema before any commercial discussion concludes. We would rather you find a mismatch during evaluation than after signature.

What rights do we get over models trained on the data?

Model-training rights, derived-work ownership, redistribution limits and retention are all set out explicitly in the licence. Models you train remain yours; the underlying dataset does not become yours. Exclusivity over defined modality and pathology combinations is negotiable.

How do you guarantee the data is genuinely de-identified?

De-identification runs inside the source hospital network before transfer, and studies that fail validation are never transmitted. Each release carries an attestation describing the method and its validation result. We can also walk your security team through the pipeline under NDA.

Is there patient-level linkage or longitudinal follow-up?

Where a partner institution can lawfully support it, studies from the same pseudonymous subject can be linked within a dataset so prior and follow-up imaging stay associated. This is scoped per engagement, because it depends on the source institution’s governance.

What about data residency?

Datasets are held in encrypted cloud storage with configurable regional residency, so a licensee operating under EU or US constraints can be accommodated. Residency requirements should be raised during scoping, not after.

How current is the data?

Archives are historical by nature, which is what makes them available at volume. Date ranges are disclosed per dataset, and where a study requires recent acquisition parameters or a specific protocol, commissioned collection is the right route.

Data licensing

Tell us what you need to prove. We will scope the data.

Describe the model, the indication and the regulatory milestone. We will come back with what is available, what is in onboarding, and what we can commission.

  • Every study carries provenance and a de-identification attestation.
  • Annotation performed by licensed radiologists, with adjudicated review.
  • Subscription, batch acquisition and commissioned collection all available.
  • Evaluation samples released under NDA before any commitment.

The more specific you are, the more precisely we can answer.

We use these details only to respond to your enquiry. No marketing lists, no third-party sharing.